Role of chemotherapy in stages I to III non-small cell lung cancer

Chest

Volumn 116, Issue 6 SUPPL., 1999, Pages 509S-516S

  Strauss, Gary M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; LOMUSTINE; MITOMYCIN; MITOMYCIN C; NAVELBINE; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033377365     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.suppl_3.509s     Document Type: Article

References (45)

1. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89(suppl):225S-233S
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717
3. Feld R, Rubenstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 1984; 2:1352-1358
4. Immerman SC, Vanecko RM, Fry WA, et al. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg 1981; 32:23-27
5. Lad TE. Postsurgical adjuvant therapy in stages I, II, and IIIA non-small cell lung cancer. Hematol Oncol Clin North Am 1990; 4:1111-1119
6. Holmes EC. Postoperative chemotherapy for non-small cell lung cancer. Chest 1993; 103(suppl):30S-34S
7. Holmes EC, Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986; 4:710-715
8. Lad T, Rubinstein L, Sadeghi A. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 1988; 6:9-17
9. Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. J Natl Cancer Inst 1993; 85:299-306
10. Niranen A, Niitamo-Korhonen S, Kouri M, et al. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol 1992; 10:1927-1932
11. Non-small Cell Lung Cancer Collaborative Group, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311:899-911
12. Feld R. Chemotherapy as adjuvant therapy for completely resected non-small cell lung cancer: have we made progress? J Clin Oncol 1996; 14:1045-1047
13. Mountain CF. Prognostic implications of the international staging system for lung cancer. Semin Oncol 1988; 15:236-245
14. Mountain CF. Value of the new TNM staging system for lung cancer. Chest 1989(suppl); 96:47S-49S
15. Mountain CF, Greenburg SD, Fraire AE. Tumor stage in non-small cell carcinoma of the lung. Chest 1991; 99:1258-1260
16. Green MR. Multimodality therapy for solid tumors. N Engl J Med 1994; 330:206-207
17. Dillman RO, Seagren S, Propert K, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990; 323:940-945
18. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-1215
19. Sause W, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 1995; 87:198-205
20. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I-II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with > 69.6 Gy in favorable patients with radiation therapy oncology group stage III non-small cell lung carcinoma: report of radiation therapy oncology group 83-11. J Clin Oncol 1990; 8:1543-1555
21. Le Chevalier T, Arriagada R, Quoiz E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83:417-423
22. Le Chevalier T, Arriagada R, Tarayre M, et al. Correspondence-significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma [letter]. J Natl Cancer Inst 1992; 84:58
23. Schaake-Koning C, Van Den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 524-530
24. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. Ann Intern Med 1996; 125:723-729
25. Green MR. Multimodality therapy in unresected stage III non-small cell lung cancer: the American Cooperative Groups' experience. Lung Cancer 1995; 12(suppl 1):S87-S94
26. Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40:266-274
27. Elias AD, Skarin AT, Gonin P, et al. Neoadjuvant treatment of stage IIIA non-small cell lung cancer: long-term results. Am J Clin Oncol 1994; 17:26-36
28. Elias AD, Skarin AT, Leong T, et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 1997; 17:147-161
29. Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10:1237-1244
30. Sugarbaker DJ, Herndon J, Kohman LJ, et al. Results of Cancer and Leukemia Group B Protocol 8935: a multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg 1995; 109:473-485
31. Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol 1997; 15:712-722
32. Martini N, Kris M, Fhelinger B, et al. Preoperative chemotherapy for stage IIIA (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-1374
33. Burkes RL, Ginsberg RJ, Sheperd FA, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small cell lung cancer: results of a Toronto phase II trial. J Clin Oncol 1992; 10:580-586
34. Reddy S, Lee MS, Bonomi P, et al. Combined modality therapy for stage III non-small cell lung cancer: results of treatment sand patterns of failure. Int J Radiat Oncol Biol Phys 1992; 24:17-32
35. Weiden P, Piantadosi S. Preoperative chemotherapy (cisplatin and flourouracil) and radiation therapy in stage III non-small cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 1991; 83:266-272
36. Albain DK, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13:1880-1892
37. Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12:539-547
38. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995; 13:452-458
39. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330:153-158
40. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994; 86:673-680
41. Pass HI, Pogrebnick HW, Steinberg SM, et al. Randomized trial of neoadjuvant therapy fur lung cancer: interim analysis. Ann Thorac Surg 1992; 53:992-998
42. Elias AD, Herndon J Kumar P, et al. A phase III comparison of "best local-regional therapy" with or without chemotherapy for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): preliminary results [abstract]. Proc Am Soc Clin Oncol Annu Meet 1997; 16:448a
43. Rosell A, Font A, Pitfarre A, et al. The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC. Chest 1996; 109(suppl):102S-106S
44. Strauss GM, Herndon JE, Sherman DD, et al. Induction chemoradiation followed by surgery in stage IIIA non-small cell carcinoma of the lung (NSCLC): long term results of Cancer and Leukemia Group B protocol 8634 [abstract]. Proc Am Soc Clin Oncol Annu Meet 1996; 15:376
45. Kumar P, Herndon J, Langer M, et al. Patterns of disease failure after trimodality therapy of non-small cell lung carcinoma pathologic stage IIIA (N2). Cancer 1996; 77: 2393-2399